CJC-1295 – with DAC

CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH) developed for research investigating endocrine signalling pathways.
In laboratory environments, the CJC-1295 peptide is studied for its interaction with receptors involved in growth hormone signalling and metabolic regulation.

Within research peptide markets, CJC-1295 is frequently discussed alongside peptides such as
IGF-1 LR3, which participates in downstream growth factor signalling pathways.
Structured product pages allow researchers to review peptide classification, biochemical mechanisms and
laboratory research context before selecting materials. You can browse the full
research peptides catalogue for related compounds.

Mechanism of Action

• GHRH receptor interaction: Activation of growth hormone signalling pathways
• Pituitary signalling pathways: Regulation of endocrine response models
• Growth factor pathway stimulation: Investigation of downstream IGF-1 signalling
• Hormonal signalling research: Study of metabolic and endocrine communication pathways

Current Research Focus

• Growth hormone signalling pathway investigation
• Endocrine regulation research models
• Growth factor signalling studies
• Metabolic and hormonal pathway research

CJC-1295 Research Context

CJC-1295 research continues within experimental environments where investigators study growth hormone
signalling pathways and endocrine system regulation. Scientific understanding continues to evolve as
further controlled laboratory and preclinical studies emerge.

This page presents investigational context in a structured format suitable for research-focused audiences.
It avoids medical claims or usage guidance and instead summarises peptide classification, signalling
pathways and areas of laboratory investigation.

Key Notes